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Abstract Breast cancer is the most common neoplasm
affecting women in the western world with an average
frequency of 1 in 11, developing the malignancy and it is
second most common cancer in India. Variations in serum
levels of biochemical parameters especially alkaline
phosphatase (ALP) changes may be of great help in diag-
nosis of breast carcinoma. Serum ALP activity was assayed
in 388 histopathologically proven breast cancer patients
using spectrophotometric methods and monitored associa-
tion with cancer stages. Breast cancer is a female-biased
disease and our study was conducted in a group of female
patients with mean age of 48.67 ± 8.32 years. A signifi-
cant increase in levels of ALP (809.65 ± 145.97 IU/L)
was observed in stage IV of the disease. The logistic
regression study gave a significant result (P \ 0.001) when
we compared the group of ALP level ([500 IU/L) with
metastatic presentation. The present study besides being
cost effective suggested the usefulness of ALP in differ-
entiating breast cancer stages and metastasis.
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Introduction
Alkaline phosphatases [ALPs; orthophosphoric monoester
phosphohydrolase (alkaline optimum) EC 3.1.3.1] are a
group of phosphatidylinositol-anchored membrane pro-
teins with wide substrate specificity (Fishman 1987;
Harris 1990). It comprises a group of enzymes that
catalyze the hydrolysis of phosphate esters in an alkaline
environment, generating an organic radical and inorganic
phosphate (Reichling and Kaplan 1988a, b). Like other
enzymes, ALP has many isoenzymes. In healthy adults,
this enzyme is mainly derived from the liver, bones and
in lesser amounts from intestines, placenta, kidneys and
leukocytes (Friedman et al. 1996). An increase in serum
ALP levels is frequently associated with a variety of
diseases such as extrahepatic bile obstruction, intrahe-
patic cholestasis, infiltrative liver disease, hepatitis, can-
cer, etc. However, the elevation of ALP less than three
times the normal level is generally considered to be
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non-specific and insufficient to provide a definite diag-
nosis (McIntyre and Rosalki 1991).
Markedly elevated serum ALP, hyperalkalinepho-
sphatasemia is predominantly seen with more specific
disorders, including malignant biliary obstruction, pri-
mary biliary cirrhosis, primary sclerosing cholangitis,
hepatic lymphoma, breast cancer and sarcoidosis
(Neuschhwander-Terti 1995). On the other hand, according
to a recent study (Maldonado 1998), sepsis and malignant
obstructions are identified as common causes of hyper-
alkalinephosphatasemia, whereas diffuse liver metastases as
well as a number of benign disorders are relatively less
common causes of hyperalkalinephosphatasemia.
Cancer is cured potentially if it is detected early when
the tumor is small enough and may be completely removed
surgically. However, most cancers do not produce any
symptoms until the tumors are either too large to be
removed surgically or cancerous cells have already spread
to other tissues as generally observed in metastasis (Mishra
et al. 2004). Hence, there is a need to detect cancer at an
early stage. Biochemical parameter like ALP will help to
monitor the disease.
In order to determine the diseases associated with
markedly elevated serum ALP levels among breast cancer
hospitalized patients, a review was made of medical
records of individuals in whom an ALP level was two- to
threefold greater than normal ALP level in Department of
Surgical Oncology, Sir Sundarlal Hospital, Banaras Hindu
University, Varanasi (UP), INDIA.
Methods
Study population and clinical evaluation of patients
This consecutive cluster study included all patients who
attended the OPD for cancer diagnosis and treatment at
the Surgical Oncology Department, Sir Sundarlal Hos-
pital, Banaras Hindu University. Exclusion criteria
included patients \18 years of age, who received prior
treatment in the form of chemotherapy/radiotherapy/sur-
gery and patients who were mentally incapable of giving
their own consent.
If the patient met the appropriate criteria, we visited
the patient before surgery to explain the study and asked
for patient’s participation. On receiving consent from the
patient, we conducted a 30-min interview with the
patient. Data involving presentation, diagnosis and stag-
ing were collected from office and hospital charts, and a
face-to-face interview with the patient was done. The
interview was mainly based on a predesigned question-
naire that included several questions about age, resi-
dence, health care and utilization.
Sample and data collection
Five milliliters of whole blood samples were collected
from each subject into plain tubes with utmost care to avoid
pre-analytical errors. Serum was extracted for analysis of
ALP. The activities of ALP were determined using the
enzymatic method (King 1946).
The normal value of ALP is 20–140 IU/L. Normal value
ranges may vary slightly among different laboratories.
A retrospective case review was made on hospitalized
patients who had an ALP level C500 IU/L. The review of
the patient’s medical records during the period of study
identified 388 cases with a conclusive diagnosis for further
analysis.
Statistical analysis
Association of ALP level was compared among the
different stages of breast cancer. Two-tailed tests were
used at all times, and statistical significance was set a
priori at P \ 0.05. Statistical analyses were performed
with SPSS for Windows 16.0. All univariate analyses
used ANOVA and Chi-square tests. Logistic regression
was performed to evaluate ALP level associated with the
metastasis.
Result and discussion
Breast cancer is leading cause of death all over the
world, but till date there is a very little knowledge about
the biological markers that help to diagnose the disease.
Biochemical parameter like ALP evaluation is an inex-
pensive and potential marker for early detection of
cancer that helps to diagnose the people of developing
countries. Most data indicate that the elevation of serum
ALP occurs because of the accelerated de novo synthesis
of the enzyme and subsequent regurgitation into the
serum (Reichling and Kaplan 1988a, b; Friedman et al.
1996). A number of diseases are related to the elevation
of serum ALP levels.
The breast cancer is a female-biased disease; the
frequency of the disease in male patient is very low in
comparison with female. It is evident from the present
study as in Table 1 that the breast cancer arises in a
female before the age of 50 years (48.67 ± 8.32 years),
whereas in a male, the mean age of onset is 54.29 years.
It suggests that this disease is hormone biased. Younger
age was found to be at high risk (Somdatta and
Baridalyne 2008) while another case–control study of
Rao et al. (1994) conducted in India found that the mean
age of breast cancer patients was 46.2 years.
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The distribution of patients according to various stages
of cancer is indicated in Fig. 1. The result of the current
study showed a significant increased level of ALP with the
advancement of the disease. Table 2 shows the mean ALP
levels at stage I, II, III and IV as 161.15 ± 110.06,
299.58 ± 111.60, 517.69 ± 110.28 and 809.65 ± 145.97,
respectively.
Table 3 shows the comparison between the two
groups of ALP level that is less than 500 IU/L and more
than 500 IU/L with cancer stage. Out of 62 cancer
patients of stage IV, the ALP was more than 500 IU/L in
61 patients.
ALP has consistently been shown to predict bone
metastases, and to some extent liver metastases, as
expected on the basis of its biological activity. While some
studies have reported fairly high sensitivity of ALP for
bone and overall metastases detection, these studies
included the use of specific isoenzymes in addition to total
ALP values [Cancer Study Group (IBCSG) 1995]. The
result of the present study showed higher serum ALP levels
in the advanced stage of breast cancer patients (Table 4). In
present study, logistic regression showed a high significant
result and explored [500 IU/L ALP level as strongly
associated with metastasis.
Similarly Vanhoof et al. (1992) and Stieber et al.
(1992) did not find any significant difference in ALP
levels in non-metastatic breast cancer, despite the fact
that some others have also revealed a significant rise in
ALP in metastasis (Ramaswamy et al. 2000; Lamerz
et al. 1993) suggesting involvement of bone and liver.
A recent study of Mishra et al. (2004) also found per-
sistent rise of ALPs level in metastasis (Ehrmeyer et al.
1978; Larson et al. 1976).
The increase in ALP level as noticed in our study also
indicates that the disease had metastasized either to bone or
liver.
Conclusion
Women with breast cancer have ALP activities generally
higher than normal healthy women. The progressive
increase in the serum ALP activities with breast cancer is
an indication of metastasis. The measurement of this
parameter may be an useful diagnostic tool in monitoring
the disease, its progression and treatment in areas where
the facilities for sophisticated studies are not readily
available.
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Table 1 Age and sex distribution
Breast cancer patient (N = 388) Mean age
Male (N = 7) 54.29 ± 7.25
Female (N = 381) 48.67 ± 8.32
Fig. 1 Distribution of cancer patients stage group in the study cohort
(N = 388)
Table 2 Distribution of alkaline phosphatase level with disease stage
Breast cancer stage Alkaline phosphatase (IU/L)
Stage I 161.15 ± 110.06
Stage II 299.58 ± 111.60
Stage III 517.69 ± 110.28
Stage IV 809.65 ± 145.97
Table 3 Association of disease stage with alkaline phosphatase level
Parameter Disease stage P value
I II III IV
Alkaline phosphatase \0.001
\500 IU/L 76 134 39 1
[500 IU/L 6 6 65 61
Table 4 Association of alkaline phosphatase with metastasis of
disease
Variable Odds ratio 95 % confidence interval (CI) P value
Lower Upper
Alkaline phosphatase level
\500 IU/L 1.0 – – –
[500 IU/L 197.260 26.89 1446.56 \0.001
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